In February, Amgen invited Australian dermatologists to the launch of Otezla (apremilast) for patients with chronic plaque psoriasis now listed on the Pharmaceutical Benefits Scheme.1,2 International guest speaker Dr Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan was joined by local faculty members Dr Diana Rubel and ...
Psoriasis
Otezla®: A Post-Topical Option for Psoriasis
23 Mar 2021
Sponsored by Amgen Australia Pty Ltd